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Abstract
The Moyamoya disease [MMD] is a cereberovascular disorder characterized by 
progressive stenosis of intracranial internal carotid arteries and compensatory col-
lateral formation at the base of the brain, mainly around the circle of Willis. When 
no particular associated risk factors can be identified, it is termed as Moyamoya 
disease. However, it may be associated with other neurological and extra- neuro-
logical disorders where it is termed as Moyamoya syndrome [MMS]. The condition 
is predominantly seen in East Asia and has bimodal age of distribution. The clinical 
manifestations are also age dependant with ischemia predominating in childhood 
and hemorrhagic manifestations being more common in adults. The pathogenesis 
is not entirely known, but genetic susceptibility is believed to be an important 
predisposing factor. The Suzuki staging system is most widely used for evaluation 
and staging of Moyamoya disease. The gold standard diagnostic modality is cerebral 
angiography but magnetic resonance imaging [MRA] has also been employed for 
diagnosis. Treatment is primarily surgical revascularization which is of 3 types: 
direct, indirect or combined revascularization. Although the role of revascular-
ization surgery has been well established for ischemic MMD, the ideal surgical 
approach and the role of surgery in hemorrhagic MMD remains controversial.
Keywords: moyamoya disease, moyamoya syndrome, stroke, cerebral angiography, 
revascularization
1. Introduction
Moyamoya disease [MMD] is a form of chronic cerebrovascular occlusion 
characterized by occlusion of terminal internal carotid artery [ICA] along with a 
network of collateral vessels at the base of the brain. The disease was first brought 
to light by Takeuchi and Shimizu, where they described a young man with bilateral 
occlusion of ICA which was found to be due to congenital hypoplasia rather than 
atherosclerotic lesion [1]. Similar cases have been described in Japanese litera-
ture. After that, the condition came to be known by various names and the term 
‘spontaneous occlusion of the circle of Willis’ by Kudo gained popularity [2]. The 
disease was finally coined ‘moyamoya’ by Suzuki and Takaku based on the abnormal 
vascular network at the base of the brain that resembles ‘vague or hazy puff of 
smoke’ which is called moyamoya in Japanese [3].
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This cerebral angiopathy is broadly termed ‘moyamoya phenomenon’ compris-
ing of two nosological entities. The cerebrovascular syndrome is called ‘Moyamoya 
syndrome’ [MMS] when it is associated with neurological and extra neurologi-
cal diseases like Neurofibromatosis 1 [NF1], Down syndrome, thyroid disease, 
cranial irradiation, sickle cell anemia, among other pathological conditions [4]. 
The Guidelines of the Research Committee on the Pathology and Treatment of 
Spontaneous Occlusion of Circle of Willis defined isolated moyamoya angiopathy as 
being idiopathic and called it ‘Moyamoya disease’ [5].
MMD is more common in Asian ethnicities as compared to the Western popula-
tion [6]. The increased prevalence in Japan, Korea and other East Asian countries 
raised genetic predisposition to this condition. Subsequently, Kamadaet al. identi-
fied a susceptibility gene, Ringin Protein 213 [RNF 213], and it was seen that this 
gene was positively associated with familial MMD [7]. Symptomatology of MMD 
varies according to the age group. Cerebral ischemia is more common in the pedi-
atric than in the adult age group, whereas, the hemorrhagic type is more common 
in >40 years of age. Only one type predominates in a particular patient, but the 
symptoms are often recurrent. The disease diagnosis often rests upon angiography, 
and revascularization procedures are performed to avoid recurrence of symptoms. 
The lack of understanding of the exact pathophysiologic mechanism of MMD limits 
the development of treatments to prevent vascular damage.
2. Methods used
A literature search was conducted using PubMed. The keywords used were 
Moyamoya disease, Moyamoya syndrome, ‘puff of smoke’, Suzuki classification, 
angiography, revascularization procedures etc. Relevant articles were reviewed in 
detail. The search was filtered to include as many recent publications as possible. An 
effort was made to compile and highlight the key differences in the disease’s clinical 
profile from East to West.
3. Epidemiology
For a very long time, Moyamoya disease was thought to be a disease of Asian 
lineage, but now it has been observed to be prevalent across the world in people 
with many ethnic backgrounds. MMD has been most extensively studied in Japan, 
where it is the most common pediatric cerebrovascular disease [8]. It shows a 
prominent East–West gradient, with a in East Asian countries ten times higher than 
the Western countries [9]. MMD is most frequently seen in Japan, with an incidence 
of 0.35–1.13/1,00,000/year and a prevalence of 3.16–10.5/1,00,000 [10]. In a study 
done in Hokkaido, Japan, 267 new cases were diagnosed between 2002–2006 [8]. 
The incidence and prevalence were also found to be high in other Asian countries 
like Korea, China and Taiwan [11]. The incidence in all these countries is found 
to be increasing over the years, most likely due to advancements in diagnostic 
modalities and a better understanding of the genetic factors linked to the disease 
[12]. Studies from outside Asia are very few. The incidence in Washington state and 
California was 0.086/1,00,000, but in them the incidence in Asian Americans was 
4.6 times that of White [9]. In Europe, the incidence of MMD was 1/10th of that in 
Japan. North America’s incidence was as low as 0.09/1,00,000 individuals, although 
an increasing trend is now being noted [13].
A similar bimodal age distribution is seen across the world, with the first peak 
occurring at 5–14 years in the pediatric population and around 4th decade in 
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adulthood [5]. In Japan, family history is present in 10–15% of cases, and the risk of 
the disease in a family member is about 30–40 times higher than the general popu-
lation. A familial predisposition was less commonly seen in European countries. 
In most countries, the disease was more frequently seen in females, with male to 
female ratio ranging from 1:1.8 to 1:2.2 [10, 14]. These epidemiological parameters 
remained constant from East to West as evident in the literature review from across 
the world by Kim et al. [6].
4. Pathology
The pathological features have been described based on autopsy findings of 
cases of MMD. The most common lesion is intracranial hemorrhage, which occurs 
in basal ganglia, thalamus, hypothalamus and brain stem. The intracranial hem-
orrhage may show intraventricular extension. Other findings are subarachnoid 
hemorrhage and small infarcts in the capsule- ganglionic area [14]. The main 
pathological findings according to the vessels involved are mentioned below.
a. The Circle of Willis: The distal ends of the internal carotid artery, Circle of 
Willis and its major branches are narrowed, tapered and often occluded. The 
occlusion is because of intimal thickening with marked attenuation of media. 
The intimal thickening is composed of smooth muscle cell proliferation  
rather than lipid and lipid-laden macrophages deposition, as seen in  
atherosclerosis [15].
b. Perforating vessels: The branches of Circle of Willis, anterior choroidal arteries, 
posterior cerebral arteries become dilated. Numerous dilated and tortuous 
vessels then originate from these arteries to penetrate the base of the brain. 
Aneurysm formation can also be seen. These small arteries can be enlarged 
with thin-walled or thick-walled with luminal stenosis [16].
c. Leptomeningeal Vessels: Angiographic findings in MMD reveal leptomeningeal 
anastomosis between the three main cerebral arteries and transdural anas-
tomosis from external carotid arteries. These form the abnormal collateral 
circulation seen as the ‘puff of smoke’ [17].
d. Other features: Intracranial aneurysms, stenosis in extracranial arteries like 
carotid, renal, pulmonary arteries, etc.
Thus, the pathology of the disease can be viewed as ICA [Internal carotid 
artery] to ECA [External carotid artery] prism, where the contribution of ICA to 
cerebral blood supply gradually decreases, and the compensatory vascular network 
is formed which is predominantly fed by ECA.
5. Pathogenesis
The mechanisms leading to the above-mentioned pathology are not entirely 
known. It is not clear what leads to migration and proliferation of smooth muscle 
cells in the intima and leads to its thickening. Moreover, why this thickening 
happens only in the circle of Willis is unknown. Many features of the disease point 
towards a hereditary predisposition- high incidence in Japanese people, familial 
occurrence, association with other congenital disorders like sickle cell anemia, 
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neurofibromatosis, Down syndrome, etc. A multifactorial mode of inheritance has 
been suggested. A possible linkage of the disease with markers located on chromo-
some 6, chromosome 17, chromosome 8q23 has been suggested [18–20]. Recently, 
a genetic locus in the Ring Finger Protein [RNF] 213 gene was also associated 
with MMD [7]. A higher carrier rate in Eastern Asia probably explains the higher 
prevalence of the disorder in Japan and other eastern Asian countries as compared 
to the Western world [21].
Moyamoya angiopathy has been identified with many genetic disorders like 
Neurofibromatosis 1, Noonan syndrome, Costello syndrome, Sickle cell disease, 
GUCY1A3 mutations, BRCC3/MTCP1 gene mutation, Down syndrome, Turner 
syndrome, etc. [19] Moyamoya disease associated with other familial or acquired 
conditions has also been termed as ‘quasi-MMD’. It was noted that unilateral presen-
tation was more common than bilateral and hemorrhagic manifestations were less 
common in quasi- MMD [21].
Although genetic predisposition to the disease exists, the majority of cases are 
sporadic. Certain acquired factors have been suggested for disease progression. 
These include vasculitis [3], infections [20], cranial trauma [22], post-irradiation 
state [23] to name a few.
6. Clinical features
The pathological changes in cerebral arteries lead to cerebrovascular events 
in Moyamoya disease. Two peaks have been identified, at around ten years and 
30–40 years. The peak occurs later in women than in men [24].
The symptoms can be classified in the following four main heads  
(Figure 1) [13].
Transient ischemic attacks [TIA] and infarct may present as a variety of 
symptoms- motor paresis, sensory disturbance, speech disturbances, alteration 
of consciousness [25]. Whereas these symptoms present acutely, mental decline, 
dyskinesias tend to progress over the years. Dilated collateral vessels in basal ganglia 
have been implicated in the development of choreiform movements [26]. Bilateral 
disease is associated with cognitive deficits. Hemorrhagic type is more common in 
adults >40 years of age and most commonly present with impaired consciousness. 
Irrespective of the primary pathology [ischemic/hemorrhagic], the symptoms tend 
to be recurrent and usually a single pathology predominates in each individual. 
Headache is another common symptom generally seen in children <14 years old [27]. 
Dilated transdural collaterals stimulate dural nociceptors precipitating migraine-like 
headaches. Headache may also be a manifestation of chronic hypoxemia.
The symptoms are triggered by hyperventilation, such as blowing/crying due to 
decreased cerebral blood flow secondary to CO2 washout. Worsening is also seen 
Figure 1. 
Clinical symptoms of Moyamoya disease.
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with infection of the upper respiratory tract. Hypertension and aging often con-
tribute to hemorrhage, which may occur at repetitive intervals. Massive bleeding 
may even lead to death. Epilepsy, as a manifestation of the disease, is usually seen in 
children less than ten years of age [28].
The clinical features also tend to vary from East to West. The ischemic mani-
festations are more predominant in the US [United States] than in other eastern 
countries. The rate of hemorrhagic disease in adults in Asian countries is higher 
[42%] than in those of Asian descent residing in the US [29]. The disorder’s 
overall spectrum remains constant worldwide, with ischemic manifestations 




Angiography is the gold standard for diagnosis and assessing disease progres-
sion. The hallmark findings of cerebral angiography are occlusion of intracranial 
internal carotid arteries (Figure 2) and abnormal smog-like arteriolar network 
[moyamoya vessels] at the base of the brain (Figure 3). The Circle of Willis and 
its main branches, leptomeningeal vessels and transdural anastomosis between 
ophthalmic artery, external carotid artery and vertebral artery are frequently seen. 
Involvement of posterior circulation is less commonly observed.
Suzuki et al. staged the disease progression into the following stages based on 
the angiographic findings [3, 22, 27].
1. Narrowing of the carotid forks
2. Initiation of moyamoya[dilated major cerebral artery and a slight network of 
collaterals]
3. Intensification of moyamoya with the disappearance of middle and anterior 
cerebral arteries
4. Minimization of moyamoya [disappearance of posterior cerebral artery and 
narrowing of individual moyamoya vessels]
5. Reduction of moyamoya [disappearance of main cerebral arteries, further min-
imization of moyamoya, increase in collaterals from external carotid arteries]
6. Disappearance of moyamoya [complete disappearance of moyamoya with 
blood flow derived only from the external carotid artery and vertebrobasilar  
system]
Apart from these changes, aneurysm formation can also be seen in angiography. 
A revised version of Suzuki staging system was given by Mugikura et al. (Table 1), 
where staging is done based on angiographic severity of stenosis of the middle 
cerebral artery and anterior cerebral artery [30].
Both the staging systems highlight that with the progression of the disease, the 
contribution of blood supply from ICA decreases and an intricate collateral network 




Neuroimaging of a 40 years old lady who presented with ICH. Non-contrast CT axial sections of brain  
(a, b, c) show intraventricular hemorrhage involving bilateral lateral ventricles (L > R), third and fourth 
ventricle. Angiographic images (d, e) show occlusion of the supraclinoid segment of the left internal carotid artery 
and attenuation on the right side with lenticulostriate collaterals showing a “puff of smoke” appearance (f).
Figure 3. 
Neuroimaging of a young boy of 6 years of age who presented with recurrent ischemic strokes. MRI brain axial 
sections show altered signal intensity areas hypointense on T1 (a) and hyperintense on T2 (b, c)) in bilateral 
frontoparietal cortex involving the MCA territory. Angiographic images show multiple tortuous collaterals 
involving both anterior (d) and posterior circulation (d, e, f) giving the typical “puff of smoke” appearance 
on cerebral DSA (f).
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7.2 Computed tomography [CT]
CT scan shows hyperdensities in basal ganglia, thalamus, ventricular system and 
subarachnoid spaces in the hemorrhagic type of MMD. In the ischemic type of the 
disease, lacunar infarcts can be seen as the areas of hypodensities. When contrast-
enhanced, tortuous and curvilinear vessels in basal ganglia can be visualized which 
represent the moyamoya vessels.
Magnetic Resonance Imaging and Angiography [MRI and MRA].
MRI and MRA provide visualization of the arterial tree without being invasive 
as conventional angiography. In addition to this, MRI also helps demonstrate small 
ICA Stage Angiographic findings
I Mild to moderate stenosis around carotid bifurcation, absent/slightly developed moyamoya, 
ACA/MCA branches opacified in anterograde fashion
II Severe stenosis around carotid bifurcation, well developed moyamoya, several of ACA/MCA 
branches opacified in anterograde fashion
III Occlusion of proximal ACA/MCA, well developed moyamoya, only a few of ACA/MCA 
branches are faintly opacified in anterograde fashion through the mesh work of ICA 
moyamoya
IV Complete occlusion of proximal ACA and MCA, small amount of moyamoya, no 
opacification of either ACA/MCA branches in anterograde fashion
ACA- anterior cerebral artery, MCA- middle cerebral artery, ICA- internal cerebral artery.
Table 1. 
The angiographic ICA staging system modified by Mugikura et al.
Score for each artery MRA finding
Internal cerebral artery
0 Normal
1 Stenosis of C1




1 Stenosis of M1
2 Discontinuity of the M1 signal
3 Invisible
Anterior cerebral artery
0 Normal A2 and blood vessels distal to A2
1 Signal decrease A2 and its distal blood vessels
2 Invisible
Posterior cerebral arteries
0 Normal P2 and blood vessels distal to P2
1 Signal decrease P2 and its distal blood vessels
2 Invisible
Table 2. 
The classification and scoring based on the MRA findings- Score of each artery.
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subcortical lesions that are difficult to identify on the CT scan. MRA helps to identify 
the stenotic distal end of the internal carotid artery, small moyamoya vessels and 
dural anastomosis between external carotid arteries and vessels of the posterior 
circulation.
The classification and scoring based on the MRA findings are given above in 
Tables 2 and 3. This MRA scoring system also finds its place in the 2012 Guidelines 
for the Diagnosis and Treatment of MMD in Japan [5].
7.3 Ultrasonography
In patients with moyamoya disease, the involvement of many extracranial 
arteries like external carotid arteries, aorta, pulmonary artery, celiac artery, and 
renal artery has been described. Characteristic signs like ‘ champagne bottleneck 
sign’ seen due to reduction in the diameter of proximal ICA and ‘diamond reversal 
sign’ due to smaller ICA diameter compared to external carotid artery have been 
demonstrated [31].
Though all the diagnostic modalities contribute to identifying and staging 
abnormal vasculature, angiography remains the mainstay of diagnosis. It is also 
helpful in documenting the postoperative resolution of moyamoya.
Electroencephalography [EEG].
The following EEG findings have been seen in moyamoya disease [32]:
1. Diffuse, bilateral, low voltage, slow spike and wave
2. ‘Buildup’ phenomenon- a diffuse pattern of slow waves
3. ‘Rebuildup’ phenomenon- diffuse slow waves during hyperventilation. This 
rebuild up phenomenon is seen due to decreased pCO2 on hyperventilation 
leading to cerebral ischemia and vasoconstriction.
8. Diagnostic guidelines
The advancements in various diagnostic modalities lead to the formulation of 
diagnostic guidelines for Moyamoya disease shown in Table 4 [5].
8.1 Treatment
Moyamoya disease is a chronic progressive disease described earlier, leading 
to recurrent strokes due to internal carotid artery occlusion and ischemia due to 
narrow, low caliber collaterals. The illness’s mainstay is revascularization surgery 





MRA: Magnetic Resonance Imaging.
Table 3. 
The classification and scoring based on the MRA findings – MRA total Score.
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to increase the intracranial blood flow using extracerebral blood vessels by direct 
bypass or pialsynangiosis. The decision for surgical intervention is based on the 
patient’s age, symptomatic/asymptomatic disease, ischemic/hemorrhagic manifes-
tations, presence/absence of aneurysm and risk of recurrence.
The indication of surgery can be briefly summarized as follows in Figure 4 [33].
8.2 Risk factors for disease recurrence
Moyamoya disease is known to progress over the years. The disease progression 
rate was reported to be approximately 20% over six years in those managed con-
servatively [34]. The risk factors of disease progression and subsequent ischemic 




4. Family history positive [35]
5. Posterior circulation was also recognized as a decisive risk factor for ischemic 
stroke [36].
A. Cerebral angiography should present at least the following findings:
1. Stenosis/occlusion at the terminal portion of ICA and/or at the proximal portion of ACA 
and/or MCA
2. Abnormal vascular network in the vicinity of stenotic/occluded vessels
3. Bilateral findings
B. Conventional angiogram not required when MRI/MRA demonstrate following findings:1.
1. Stenosis/occlusion at the terminal portion of ICA and/or at the proximal portion of ACA and/or 
MCA on MRA
2. Abnormal vascular network in the basal ganglia on MRA[>2 flow voids in basal ganglia in MRI].
3. Bilateral findings
C. Absence of arteriosclerosis, autoimmune disease, meningitis, brain neoplasm, down syndrome, 
Recklinghausen’s disease, head trauma, irradiation to head, others.
D. Pathological findings:
1. Stenosis/occlusion due to intimal thickening at the terminal ICA, usually on both sides
2. Arteries of Circle of Willis show varying degree of stenosis/occlusion of intima, attenuation of 
media and waving of internal elastic lamina
3. Numerous small vascular channels around the Circle of Willis
4. Reticular conglomerates of small vessels in pia matter.
Definitive case: A/B + C[In children, a case that fulfills A1 and A2 or B1 and B2 on one side and 
remarkable stenosis of terminal ICA on opposite side is also included.]
Probable case: A1 and A2 [or B1 and B2] and C [unilateral]
Table 4. 
Diagnostic guidelines for Moyamoya disease.
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Moyamoya disease is a progressive disease, and symptomatic progression is seen in 
approximately two-thirds of patients. [29]In a large meta-analysis, where 1,156 people 
were studied, it was seen that 87% of those who underwent surgical revascularization 
showed partial or complete resolution of symptomatic cerebral ischemia [37].
A careful choice of treatment, that is, conservative vs. surgical should thus be 
made keeping in mind the above-mentioned risk factors.
8.3 Conservative treatment of mmd
The predominant manifestation of MMD is ischemic stroke. However, antiplatelet 
therapy is ineffective to prevent recurrent cerebral infarction in ischemic MMD. The 
ischemic insult in MMD patients is a consequence of hemodynamic instability. There 
is no evidence of endothelial dysfunction at the site of internal carotid artery bifurca-
tion. Therefore, increased platelet adhesion is not seen in MMD. Hence, theoretically, 
antiplatelet drugs are ineffective for preventing ischemic stroke in MMD. Moreover, 
increased risk of hemorrhage remains with antiplatelets in patients with MMD [38]. 
The annual stroke rate in patients managed conservatively is between 3.2%–15% [35].
8.4 Indication of surgical revascularization
Surgical revascularization is done to increase the cerebral blood flow and restore 
reserve capacity. The increase in cerebral blood flow prevents recurrent cerebral 
infarction. The indications for surgical revascularization are:
1. Recurrent clinical symptoms due to cerebral ischemia
2. Pediatric MMD because pediatric MMD is more progressive than adult MMD. 
Early diagnosis and intervention are of paramount importance to prevent ir-
reversible damage. In a recent study, Rosi et al. confirmed a high benefit/risk 
ratio, with better postoperative functional status and low rates for the need of 
surgical retreatment in the pediatric population undergoing surgical revascu-
larization [39].
3. Role of revascularization surgery in asymptomatic MMD with stable hemody-
namics is not well established but preferred by neurosurgeons given the disease 
Figure 4. 
Overview of the management of Moyamoya disease.
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being a progressive disorder. Risk–benefit ratio determines the feasibility of the 
surgical intervention in such patients.
4. Role of revascularization surgery in hemorrhagic stroke is controversial.
With increased understanding of MMD being familial in at least some of the 
world’s regions, it is being suggested that asymptomatic siblings and family mem-
bers should be screened for moyamoya pathology. Whenever such a condition is 
detected, it should be managed surgically, keeping in mind the illness’s progres-
sive nature.
8.5 Surgical modalities for revascularization
8.5.1 Direct revascularization
Anastomosis is formed between the superficial temporal artery and cortical 
branches of middle cerebral arteries in this procedure. For posterior circulation, 
the occipital artery is used as a donor for nteroposterior cerebral arteries’ cortical 
branches. The transdural or transcalvarial collateral channels should be preserved 
during the surgery.
The advantage of this procedure is an immediate improvement in the cerebral 
blood flow after surgery. However, the successful restoration of cerebral blood 
flow is operator dependant as it is challenging to perform. Moreover, postopera-
tive hyperperfusion syndrome may develop after surgery leading to neurological 
deterioration. Patency and amount of bypass flow may be assessed postopera-
tively by digital subtraction angiography or quantitative magnetic resonance 
angiography.
The annual stroke rate after direct revascularization was reportedly 
0–1.6% [40].
8.5.2 Indirect revascularization
The various surgical procedures are
1. Encephalomyosynangiosis[EMS] where deep temporal artery supplying the 
temporalis muscle is the vessel for neovascularization
2. Encephalo-duro-arteriosynangiosis[EDAS]: Here, superficial temporal 
artery[STA] is harvested with surrounding galea and periosteum; STA flap is 




5. Omental flap surgery
6. Multiple burr hole surgery




Indirect revascularization is relatively easier to perform than direct surgeries, 
and the incidence of hyperperfusion is also less. However, the improvement in 
cerebral revascularization takes longer than the direct surgeries where the effect is 
immediate.
After indirect revascularization, patients experienced 0–14.3% postoperative 
annual stroke rate [41].
Thus either of the indirect and direct revascularization procedures can be 
performed to rectify the underlying pathology, but the risk of recurrence is much 
less with the direct revascularization surgeries without any delay to the benefit.
8.6 Peri/postoperative complications
The following complications have been noted in the peri/postoperative 
period in MMD:
1. The risk of postoperative stroke has been estimated to be 1.6%- 16% [42].
2. The risk of perioperative ischemic complications is more in patients with 
unstable hemodynamics and advanced Suzuki stage with a lower cerebral 
blood flow.
3. Hemorrhagic stroke develops in 0.7%–8% [42].
4. Hyperperfusion syndrome- due to the chronic changes in cerebral blood  
vessels, the auto-regulatory function is lost, and the vascular reserve is de-
creased. The excessive blood flow immediately after the surgery is sometimes 
not well tolerated, leading to cerebral hemorrhage. Another factor that may 
predispose to intracranial hemorrhage is increased vascular permeability  
secondary to chronic ischemia.
5. Epidural hematoma mainly in the pediatric population.
6. Skin problems due to scalp ischemia after revascularization.
9. Conclusion
Moyamoya disease is a chronic progressive vasculopathy seen in children and 
adults, characterized by occlusion/stenosis at the terminal portions of the internal 
carotid artery and abnormal collateral network formation at the base of the brain. It 
is predominantly seen in Asian countries. It may be idiopathic [moyamoya disease] 
or associated with other disorders when it is called moyamoya syndrome. Various 
angiographic and magnetic resonance angiographic findings have been described 
which form the basis of the diagnostic guidelines for MMD. It may present as an 
ischemic/hemorrhagic stroke. It is generally managed with direct/indirect revas-
cularization surgical techniques that aim to restore the cerebral blood flow and 
prevent strokes that restore the cerebral blood flow and prevent strokes’ recurrence.
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